Skip to main content

Table 1 Demographic and clinical variables in healthcare subjects and patients with or without diabetic foot

From: Assessment of heart rate variability (HRV) in subjects with type 2 diabetes mellitus with and without diabetic foot: correlations with endothelial dysfunction indices and markers of adipo-inflammatory dysfunction

Variables DFS (n = 63) NDFS (n = 30) Healthy (n = 30) pa
Sex M/F 45/18 11/19 14/16 0.003
Hypertension (n/%) 58/92 24/80 14/46  < 0.0005
Cardiovascular events (n/%) 24/38 12/40 20/66 0.028
Stroke (n/%) 13/20 4/13 3/10 0.380
Dyslipidemia (n/%) 45/71 18/60 24/80 0.231
Smoker (n/%) 23/36 10/33 25/83  < 0.0005
Beta blocker (n/%) 20/31 13/43 12/40 0.503
Calcium channel blocker (n/%) 27/42 13/43 12/40 0.958
ACE inhibitor or ARBs (n/%) 26/41 13/43 12/40 0.965
Statin (n/%) 47/74 20/66 25/83 0.331
Antiplatelet (n/%) 28/44 10/33 13/43 0.580
GLP-1 agonist or DPP4 inhibitors (n/%) 1/1 5/16 0/0 0.002
Sulfonylurea (n/%) 1/1 11/36 0/0  < 0.0005
Metformin (n/%) 10/15 16/53 0/0  < 0.0005
Insulin (n/%) 63/100 6/20 0/0  < 0.0005
  1. DFS, diabetes foot syndrome; ARBs, Angiotensin II receptor blockers
  2. GLP-1: Glucagon-like peptide-1 receptor; DPP4 inhibitors, Inhibitors of dipeptidyl peptidase 4
  3. ap, intergroup differences among patient groups (chi-square test or Fisher’s test, as needed)